News
menopause, U.S. FDA and box warning
Digest more
A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...
Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...
JUUL GETS ITS CROWN — The FDA authorized Juul’s applications on Thursday to sell e-cigarettes in the U.S., determining ...
These symptoms could also be due to lowered testosterone levels. A 2023 study in the Journal of Clinical Endocrinology ...
The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...
MENOPAUSAL THERAPY IN FOCUS — The FDA will hold a panel discussion Thursday on hormone therapy for menopausal women, a pet ...
An article in The Journal For Nurse Practitioners found that Depo-Testosterone was the most cost-efficient TRT option, and ...
While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback